Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.61 |
| ▸ | MAOA | P21397 | 1/20 | 0.54 |
| ▸ | MAOB | P27338 | 1/20 | 0.54 |
| ▸ | CA12 | O43570 | 6/20 | 0.50 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | CA2 | P00918 | 6/20 | 0.50 |
| ▸ | CA9 | Q16790 | 6/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 4/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29991492 | 1.00 | TDP1 (0.61) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL14136077 | 1.00 | TDP1 (0.61) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL15798200 | 0.98 | TDP1 (0.58) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL13752093 | 0.94 | TDP1 (0.56) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL21107166 | 0.93 | TDP1 (0.54) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL21106609 | 0.92 | TDP1 (0.52) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL25957539 | 0.92 | TDP1 (0.52) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL25770348 | 0.91 | TDP1 (0.51) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL25756346 | 0.90 | TDP1 (0.50) | TDP1MAOAMAOBCA12CA1 | |
| SCHEMBL25756209 | 0.88 | TDP1 (0.48) | TDP1MAOAMAOBCA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11576924-B2 | Compounds for the prevention and treatment of diseases and the use thereof | GALECTIN SCIENCES, LLC (US) | 2023-02-14 | — | — | US | disclosed |
| US-20200155586-A1 | Compounds for the Prevention and Treatment of Diseases and the Use Thereof | GALECTIN SCIENCES, LLC | 2020-05-21 | — | — | US | disclosed |
| US-20200061095-A1 | Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof | GALECTIN SCIENCES, LLC | 2020-02-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200155586-A1 | Compounds for the Prevention and Treatment of Diseases and the Use Thereof | LGALS1, LGALS3BP, LGALS2 | TDP1 1922/4885MAOA 4281/4885MAOB 3767/4885 |
| US-11576924-B2 | Compounds for the prevention and treatment of diseases and the use thereof | LGALS1, LGALS3BP, LGALS2 | TDP1 1922/4885MAOA 4281/4885MAOB 3767/4885 |
| US-20200061095-A1 | Compounds for the Treatment of Systemic Insulin Resistance Disorders and the Use Thereof | LGALS1, LGALS2, LGALS4 | TDP1 3081/4885MAOA 4848/4885MAOB 4024/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.